UK-based biotech Antiverse has secured $9.3 million in Series A funding to advance its mission to develop therapeutic...
Antiverse lands $9.3M: Can it be a turning point for diseases with no effective treatments?
UK-based biotech Antiverse has secured $9.3 million in Series A funding to advance its mission to develop therapeutic...